Allergan
Search results
www .actavis .com. Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
Aug 2, 2016 · Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Allergan plc (NYSE: AGN) today announced that Teva has completed its acquisition of Allergan’s generics business (“Actavis Generics”). This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines ...
Feb 18, 2014 · Actavis Cautionary Statement Regarding Forward-Looking Statements. Statements contained in this communication that refer to Actavis' estimated or anticipated future results, including estimated ...
Feb 18, 2014 · Actavis will pay $26.04 plus 0.3306 share per Forest Labs share. That's equal to $92.65 as of Tuesday's close, following Actavis' 5% gain to 201.47. Forest Labs shot up 27.5% to 91.04.
Mar 17, 2015 · Allergan, founded in 1950 with a focus on allergy nasal drops, is expected to retain a major presence in Irvine. The new company will spend about $1.7 billion on research and development, Actavis ...
Nov 17, 2014 · Actavis anticipates that the expected permanent financing structure, consisting of a combination of new equity and debt, will support an investment grade rating and provide long-term financing ...
